Bone-Derived Extracellular Vesicles: Novel Players of Interorgan Crosstalk

Li, Yang; Yin, Pengbin; Guo, Zhongkui; Lv, Houchen; Deng, Yuan; Chen, Ming; Gu, Ya; Tang, Peifu; Zhang, Licheng

doi:10.3389/fendo.2019.00846

Cited by 10 publications

(11 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FGF23 controls renal phosphate reabsorption, modulates the production of parathyroid hormone (PTH) and 1,25-(OH)2-vitamin D. It also participates in mineral homeostasis. FGF23 acts on the kidney to increase renal phosphate excretion and to decrease 1,25-dihydroxy vitamin D (1,25D) production (Li et al, 2019;Musgrove and Wolf, 2020). FGF23 levels rose acutely in patients who underwent cardiac surgery and developed AKI, even before a significant increase in serum creatinine (Christov et al, 2013).…”

Section: Fgf23 As Biomarkers Of Aki and Ckdmentioning

confidence: 99%

Fibroblast Growth Factors in the Management of Acute Kidney Injury Following Ischemia-Reperfusion

et al. 2020

View full text Add to dashboard Cite

Ischemia-reperfusion injury (IRI), which is triggered by a transient reduction or cessation of blood flow followed by reperfusion, is a significant cause of acute kidney injury (AKI). IRI can lead to acute cell death, tissue injury, and even permanent organ dysfunction. In the clinic, IRI contributes to a higher morbidity and mortality and is associated with an unfavorable prognosis in AKI patients. Unfortunately, effective clinical drugs to protect patients against the imminent risk of renal IRI or treat already existing AKI are still lacking. Fibroblast growth factors (FGFs) are important regulators of key biological and pathological processes, such as embryonic development, metabolic homeostasis and tumorigenesis through the regulation of cell differentiation, migration, proliferation and survival. Accumulating evidence suggests that altered expression of endogenous FGFs is associated with IRI and could be instrumental in mediating the repair process. Therefore, FGFs have been proposed as potential biomarkers in the clinic. More importantly, exogenous FGF ligands have been reported to protect against renal IRI and display promising features for therapy. In this review, we summarize the evidence and mechanisms of AKI following IRI with a focus on the therapeutic capacity of several members of the FGF family to treat AKI after IRI.

show abstract

Section: Fgf23 As Biomarkers Of Aki and Ckdmentioning

confidence: 99%

Fibroblast Growth Factors in the Management of Acute Kidney Injury Following Ischemia-Reperfusion

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Bone-cell-derived EVs have various biological effects on human physiology [ 47 , 48 ]. These EVs are involved in bone remodeling and regeneration by promoting cell–cell communication between osteoclasts, osteoblasts and osteocytes via the transport of biomolecules [ 47 , 48 ]. For instance, the miR-214-3p carried by osteoclast-derived exosomes can inhibit osteoblast activity [ 48 ].…”

Section: Extracellular Vesicles In a Physiological Settingmentioning

confidence: 99%

“…These EVs are involved in bone remodeling and regeneration by promoting cell–cell communication between osteoclasts, osteoblasts and osteocytes via the transport of biomolecules [ 47 , 48 ]. For instance, the miR-214-3p carried by osteoclast-derived exosomes can inhibit osteoblast activity [ 48 ]. Furthermore, Li et al hypothesized that bone-cell-derived EVs are involved in inter-organ communication [ 48 ].…”

Section: Extracellular Vesicles In a Physiological Settingmentioning

confidence: 99%

“…For instance, the miR-214-3p carried by osteoclast-derived exosomes can inhibit osteoblast activity [ 48 ]. Furthermore, Li et al hypothesized that bone-cell-derived EVs are involved in inter-organ communication [ 48 ]. EVs can transport various factors secreted by bone cells and act as paracrine modulators of organ functions [ 48 ].…”

Section: Extracellular Vesicles In a Physiological Settingmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Chronic Kidney Disease and Uremic Toxins on Extracellular Vesicle Biology

Yaker

Kamel

Ausseil

et al. 2020

Toxins

View full text Add to dashboard Cite

Vascular calcification (VC) is a cardiovascular complication associated with a high mortality rate, especially in patients with diabetes, atherosclerosis or chronic kidney disease (CKD). In CKD patients, VC is associated with the accumulation of uremic toxins, such as indoxyl sulphate or inorganic phosphate, which can have a major impact in vascular remodeling. During VC, vascular smooth muscle cells (VSMCs) undergo an osteogenic switch and secrete extracellular vesicles (EVs) that are heterogeneous in terms of their origin and composition. Under physiological conditions, EVs are involved in cell-cell communication and the maintenance of cellular homeostasis. They contain high levels of calcification inhibitors, such as fetuin-A and matrix Gla protein. Under pathological conditions (and particularly in the presence of uremic toxins), the secreted EVs acquire a pro-calcifying profile and thereby act as nucleating foci for the crystallization of hydroxyapatite and the propagation of calcification. Here, we review the most recent findings on the EVs’ pathophysiological role in VC, the impact of uremic toxins on EV biogenesis and functions, the use of EVs as diagnostic biomarkers and the EVs’ therapeutic potential in CKD.

show abstract

“… Bone-secreted factors regulate interorgan crosstalk. Reproduced, with permission, from ( Li Y. et al., 2019 ). …”

Section: Potential Therapeutic Targets Of Ageing Skeletal Musclementioning

confidence: 99%

Advance in Drug Delivery for Ageing Skeletal Muscle

Li¹,

Chen²,

Zhao³

et al. 2020

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The age-related loss of skeletal muscle, sarcopenia, is characterized by progressive loss of muscle mass, reduction in muscle strength, and dysfunction of physical performance. It has become a global health problem leading to several adverse outcomes in the ageing population. Research on skeletal muscle loss prevention and treatment is developing quickly. However, the current clinical approaches to sarcopenia are limited. Recently, novel drug delivery systems offer new possibilities for treating aged muscle loss. Herein, we briefly recapitulate the potential therapeutic targets of aged skeletal muscle and provide a concise advance in the drug delivery systems, mainly focus on the use of nanocarriers. Furthermore, we elaborately discuss the prospect of aged skeletal muscle treatment by nanotechnology approaches.

show abstract

Bone-Derived Extracellular Vesicles: Novel Players of Interorgan Crosstalk

Cited by 10 publications

References 62 publications

Fibroblast Growth Factors in the Management of Acute Kidney Injury Following Ischemia-Reperfusion

Fibroblast Growth Factors in the Management of Acute Kidney Injury Following Ischemia-Reperfusion

Effects of Chronic Kidney Disease and Uremic Toxins on Extracellular Vesicle Biology

Advance in Drug Delivery for Ageing Skeletal Muscle

Contact Info

Product

Resources

About